TWiV 1004: Clinical update with Dr. Daniel Griffin
In his weekly clinical update, Dr. Griffin discusses the U.S. Food and Drug Administration approving Arexvy: the first respiratory syncytial virus (RSV) vaccine approved for use in the United State, association between SARS-CoV-2 and metagenomic content of samples from the Huanan Seafood Market, researchers disagree over how bad it is to be reinfected and whether COVID-19 can cause lasting changes to the immune system, virtual care and emergency department use during the COVID-19 pandemic among patients of family physicians in Canada, vaccination with BCG-Denmark did not result in a lower risk of COVID-19 among health care workers than placebo, NVX-CoV2373 vaccine efficacy against hospitalization, comparative effectiveness of the SARS-COV-2 vaccines during Delta dominance, assessment of gender-specific COVID-19 case fatality risk per malignant neoplasm type, clinical outcomes following treatment for COVID-19 with Nirmatrelvir/Ritonavir and Molnupiravir among patients living in nursing homes, timing of intubation and ICU mortality in COVID-19 patients, real-life experience with Remdesivir for treatment of COVID-19 among older adults, and how long COVID brain fog and muscle pain are associated with longer time to clearance of SARS-CoV-2 RNA from the upper respiratory tract during acute infection.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, emailBecome a patron of TWiV!
Links for this episode- FDA approves Arexvy, the first RSV vaccine approved in the US (FDA)
- Association between SARS-CoV-2 and content of samples from the Huanan Seafood Market (bioRxiv)
- Researchers disagree over how bad it is to be reinfected with COVID-19 and lasting changes to the immune system (Nature)
- Virtual care and emergency department use during the COVID-19 Pandemic among patients of family physicians (JAMA)
- Vaccination with BCG-Denmark did not result in a lower risk of COVID-19 among health care workers (NEJM)
- NVX-CoV2373 vaccine efficacy against hospitalization (Vaccine)
- Comparative effectiveness of the SARS-COV-2 vaccines during Delta (Cell)
- Assessment of gender-specific COVID-19 case fatality risk (JAMA)
- Clinical outcomes following treatment for COVID-19 with Nirmatrelvir/Ritonavir and Molnupiravir (JAMA)
- Timing of intubation and ICU mortality in COVID-19 patients (BMC)
- Real-life experience with Remdesivir for treatment of COVID-19 (JAC)
- Long COVID brain fog and muscle pain are associated with longer time to clearance of SARS-CoV-2 RNA (Frontiers)
- Contribute to our FIMRC fundraiser at PWB
- Letters read on TWiV 1004
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv
More description
In his weekly clinical update, Dr. Griffin discusses the U.S. Food and Drug Administration approving Arexvy: the first respiratory syncytial virus (RSV) vaccine approved for use in the United State, association between SARS-CoV-2 and metagenomic content of samples from the Huanan Seafood Market, researchers disagree over how bad it is to be reinfected and whether COVID-19 can cause lasting changes to the immune system, virtual care and emergency department use during the COVID-19 pandemic among patients of family physicians in Canada, vaccination with BCG-Denmark did not result in a lower risk of COVID-19 among health care workers than placebo, NVX-CoV2373 vaccine efficacy against hospitalization, comparative effectiveness of the SARS-COV-2 vaccines during Delta dominance, assessment of gender-specific COVID-19 case fatality risk per malignant neoplasm type, clinical outcomes following treatment for COVID-19 with Nirmatrelvir/Ritonavir and Molnupiravir among patients living in nursing homes, timing of intubation and ICU mortality in COVID-19 patients, real-life experience with Remdesivir for treatment of COVID-19 among older adults, and how long COVID brain fog and muscle pain are associated with longer time to clearance of SARS-CoV-2 RNA from the upper respiratory tract during acute infection.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, emailBecome a patron of TWiV!
Links for this episode- FDA approves Arexvy, the first RSV vaccine approved in the US (FDA)
- Association between SARS-CoV-2 and content of samples from the Huanan Seafood Market (bioRxiv)
- Researchers disagree over how bad it is to be reinfected with COVID-19 and lasting changes to the immune system (Nature)
- Virtual care and emergency department use during the COVID-19 Pandemic among patients of family physicians (JAMA)
- Vaccination with BCG-Denmark did not result in a lower risk of COVID-19 among health care workers (NEJM)
- NVX-CoV2373 vaccine efficacy against hospitalization (Vaccine)
- Comparative effectiveness of the SARS-COV-2 vaccines during Delta (Cell)
- Assessment of gender-specific COVID-19 case fatality risk (JAMA)
- Clinical outcomes following treatment for COVID-19 with Nirmatrelvir/Ritonavir and Molnupiravir (JAMA)
- Timing of intubation and ICU mortality in COVID-19 patients (BMC)
- Real-life experience with Remdesivir for treatment of COVID-19 (JAC)
- Long COVID brain fog and muscle pain are associated with longer time to clearance of SARS-CoV-2 RNA (Frontiers)
- Contribute to our FIMRC fundraiser at PWB
- Letters read on TWiV 1004
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv
Listen elsewhere
Available Results
Generated results are saved to your library for reuse and search.